This study identified these mutations as a cause of developed resistance; however, a separate smaller study found that JAK1/2 mutations were present in pre-treatment tumour biopsies from two patients with a high TMB but poor response to anti-PD-1 therapy, suggesting these mutations may also be a primary cause of resistance to anti-PD-1 therapy [56]. Here, JAK1 is linked to neoplasm.